Lantern Pharma Stock Price Prediction
| LTRN Stock | USD 3.11 0.04 1.30% |
Oversold Vs Overbought
50
Oversold | Overbought |
EPS Estimate Next Quarter (0.59) | EPS Estimate Current Year (1.93) | EPS Estimate Next Year (1.61) | Wall Street Target Price 20.5 | EPS Estimate Current Quarter (0.56) |
Using Lantern Pharma hype-based prediction, you can estimate the value of Lantern Pharma from the perspective of Lantern Pharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Lantern Pharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Lantern because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Lantern Pharma after-hype prediction price | USD 3.12 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Lantern |
Lantern Pharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Lantern Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Lantern Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Lantern Pharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Lantern Pharma Estimiated After-Hype Price Volatility
In the context of predicting Lantern Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Lantern Pharma's historical news coverage. Lantern Pharma's after-hype downside and upside margins for the prediction period are 0.16 and 7.23, respectively. We have considered Lantern Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Lantern Pharma is slightly risky at this time. Analysis and calculation of next after-hype price of Lantern Pharma is based on 3 months time horizon.
Lantern Pharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Lantern Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lantern Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Lantern Pharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.18 | 4.11 | 0.01 | 0.01 | 8 Events / Month | 4 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
3.11 | 3.12 | 0.32 |
|
Lantern Pharma Hype Timeline
Lantern Pharma is now traded for 3.11. The entity has historical hype elasticity of 0.01, and average elasticity to hype of competition of 0.01. Lantern is projected to increase in value after the next headline, with the price projected to jump to 3.12 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 0.32%, whereas the daily expected return is now at -0.18%. The volatility of related hype on Lantern Pharma is about 5032.65%, with the expected price after the next announcement by competition of 3.12. Net Loss for the year was (15.96 M) with profit before overhead, payroll, taxes, and interest of 0. Given the investment horizon of 90 days the next projected press release will be in about 8 days. Check out Lantern Pharma Basic Forecasting Models to cross-verify your projections.Lantern Pharma Related Hype Analysis
Having access to credible news sources related to Lantern Pharma's direct competition is more important than ever and may enhance your ability to predict Lantern Pharma's future price movements. Getting to know how Lantern Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Lantern Pharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CUE | Cue Biopharma | 0.02 | 8 per month | 5.91 | 0.11 | 20.27 | (11.51) | 67.78 | |
| TFFP | Tff Pharmaceuticals | (0.13) | 4 per month | 0.00 | (0.14) | 11.28 | (12.99) | 95.77 | |
| ELYM | Eliem Therapeutics | 0.25 | 4 per month | 0.00 | (0.19) | 6.21 | (9.35) | 34.87 | |
| INBX | Inhibrx | 1.00 | 6 per month | 2.70 | 0.02 | 5.54 | (6.11) | 16.80 | |
| ELVN | Enliven Therapeutics | (0.55) | 9 per month | 2.06 | 0.03 | 5.84 | (4.07) | 12.96 | |
| MOLN | Molecular Partners AG | (0.10) | 5 per month | 0.00 | (0.02) | 9.38 | (8.53) | 52.92 |
Lantern Pharma Additional Predictive Modules
Most predictive techniques to examine Lantern price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Lantern using various technical indicators. When you analyze Lantern charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Lantern Pharma Predictive Indicators
The successful prediction of Lantern Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Lantern Pharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Lantern Pharma based on analysis of Lantern Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Lantern Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Lantern Pharma's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 31.26 | 20.99 | 16.18 | 14.43 | Net Debt To EBITDA | 4.18 | 2.58 | 1.37 | 1.62 |
Story Coverage note for Lantern Pharma
The number of cover stories for Lantern Pharma depends on current market conditions and Lantern Pharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Lantern Pharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Lantern Pharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Lantern Pharma Short Properties
Lantern Pharma's future price predictability will typically decrease when Lantern Pharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Lantern Pharma often depends not only on the future outlook of the potential Lantern Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Lantern Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 10.8 M | |
| Cash And Short Term Investments | 41.3 M |
Check out Lantern Pharma Basic Forecasting Models to cross-verify your projections. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Return On Assets (0.28) | Return On Equity (0.45) |
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.